Zobrazeno 1 - 10
of 1 113
pro vyhledávání: '"F, Seymour"'
Autor:
Arnon P. Kater, Barbara F. Eichhorst, Carolyn J. Owen, Ulrich Jaeger, Brenda Chyla, Marcus Lefebure, Rosemary Millen, Yanwen Jiang, Maria Thadani‐Mulero, Michelle Boyer, John F. Seymour
Publikováno v:
HemaSphere, Vol 8, Iss 8, Pp n/a-n/a (2024)
Abstract Immune dysregulation is a hallmark of chronic lymphocytic leukemia (CLL). Anti‐CD20 antibodies (e.g., rituximab [R]) can be combined with venetoclax (Ven) to treat CLL. However, anti‐CD20 antibodies can increase hypogammaglobulinemia ris
Externí odkaz:
https://doaj.org/article/e7a1b35722c44499b7700a85cc48aca9
Autor:
Rory Bennett, John F. Seymour
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Chronic lymphocytic leukemia (CLL) predominantly affects older adults, characterized by a relapsing and remitting pattern with sequential treatments available for many patients. Identification of progressive/relapsed CLL should prompt close
Externí odkaz:
https://doaj.org/article/6384b34ca0754c59b1146e94a218606e
Publikováno v:
eJHaem, Vol 5, Iss 3, Pp 631-632 (2024)
Externí odkaz:
https://doaj.org/article/d70fb8305f8c4d96902ea744c1736b97
Autor:
Senthil Lingaratnam, Mahek Shah, Joseph Nicolazzo, Michael Michael, John F. Seymour, Paul James, Smaro Lazarakis, Sherene Loi, Carl M. J. Kirkpatrick
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 5, Pp n/a-n/a (2024)
Abstract The clinical application of Pharmacogenomics (PGx) has improved patient safety. However, comprehensive PGx testing has not been widely adopted in clinical practice, and significant opportunities exist to further optimize PGx in cancer care.
Externí odkaz:
https://doaj.org/article/dde6ca2c8480408196a912a6cc85e928
Autor:
Ing S. Tiong, William S. Stevenson, Meaghan Wall, Yan Zhuang Yap, John F. Seymour, Melita Kenealy, Piers Blombery, the Australasian Leukaemia & Lymphoma Group
Publikováno v:
eJHaem, Vol 4, Iss 4, Pp 1212-1215 (2023)
Externí odkaz:
https://doaj.org/article/84bfb8539c9b4cb39d8f404457cc07c4
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract In recent years, Bruton tyrosine kinase (BTK) inhibitors have provided significant advances in the treatment of patients with B-cell malignancies. Ibrutinib was the first BTK inhibitor to be approved, and it changed the standard-of-care trea
Externí odkaz:
https://doaj.org/article/0b8e7b52447c454692e67c1626b0b8f1
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-22 (2023)
Abstract Background The treatment landscape for chronic lymphocytic leukemia (CLL) continues to undergo considerable evolution. Optimal selection of initial therapy from multiple effective options provides a major challenge for clinicians, who need t
Externí odkaz:
https://doaj.org/article/9d84a95dd0164a698d00f4f306151f3d